TACE boosts surgery eligibility and doubles 5-year survival in early locally advanced cervical cancer

In stage IB3/IIA2 cervical cancer, TACE pre-treatment achieved 77.9% resectability and significantly improved 5-year survival (69.7% vs 41.0% with surgery alone, P<0.05). No survival benefit was seen when adding TACE before chemoradiation for stage IIB/IIIA disease.

• Single-center retrospective study of 187 patients with LACC (2011–2019).
• TACE reduced operative time, intraoperative bleeding, and length of stay (all P<0.05).
• Limited by retrospective design, small subgroups, and single-center data.

RadPigeon summaries are original and for information only. They are not clinical advice.